Autism is Not Caused by Terbutaline
- *Corresponding Author:
- Morrison JC
Department of Obstetrics and Gynecology
University of Mississippi Medical Center
2500 North State Street, Jackson, USA
Received date March 07, 2015; Accepted date March 16, 2015; Published date March 22, 2015
Citation: Elliott JP, Morrison JC (2015) Autism is Not Caused by Terbutaline. Autism-Open Access 5:139. doi:10.4172/2165-7890.1000139
Copyright: © 2015 Elliott JP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: To identify the rate of Autism Spectrum Disorder (ASD) in children exposed to terbutaline in utero compared to patients untreated with this beta agonist.
Methods: Members of three lay organizations collected data regarding significant childhood development problems following their pregnancy using a web-based survey.
Results: Over a 90 day period, 11,717 surveys were sent electronically to members of the high risk pregnancy organizations. Of these, 2217 members (18.9%) responded and results showed that 965(43.5%) had received terbutaline during their pregnancies. Overall 523(23.6%) reported having at least one child with some form of chronic disability and of these 128 had a child with ASD. Of fetuses with no exposure to terabutaline 79/1252 (6.3%) had a diagnosis of ASD compared to 49/965 (5.1%) who reported a history of terbutaline exposure (p=0.233). In contrast, prematurity was strongly associated with ASD as 102/128 (80%) were delivered at <36 weeks compared to 26/128 of those with ASD (20%) delivering at >36 weeks.
ASD was not associated with terabutaline exposure in pregnancy; however ASD was associated with preterm delivery.